Skip to main content
    A

    ARS Pharmaceuticals, Inc (SPRY)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $3.59
    -0.30 (-7.71%)

    Market Cap: $391.06M

    Last updated: Nov 17, 2026 at 11:06 AM ET

    ARS Pharmaceuticals, Inc (SPRY) Earnings: Report Dates and Results

    Updated Nov 5, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    ARS Pharmaceuticals (SPRY) is expected to report earnings on Mar 8, 2027. In the quarter ended Sep 30, 2026, ARS Pharmaceuticals reported EPS of -$0.36, below the -$0.34 estimate. It beat the EPS estimate in 4 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    40%(10/25)
    Avg Surprise
    +34.80%

    Upcoming Estimates

    Reports Mar 8, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus-$0.31
    Range-$0.41 - -$0.17
    6 analysts
    Revenue Consensus
    $28.65M
    Range$24.01M - $32.66M
    6 analysts
    Reports May 13, 2027 (est.)Period ending Mar 31, 2027
    EPS Consensus-$0.34
    Range-$0.41 - -$0.27
    2 analysts
    EPS Revisions
    0
    1
    30d
    EPS Estimate DriftChange to current
    90d ago-$0.25-36.0%
    60d ago-$0.39+11.7%
    30d ago-$0.39+11.7%
    7d ago-$0.39+11.7%
    Current-$0.34
    Revenue Consensus
    $24.54M
    Range$24.50M - $24.58M
    2 analysts

    Next Report

    SPRY has an expected report date of Mar 8, 2027.

    SPRY Earnings Call

    The latest SPRY earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Earnings History

    Of the 25 quarters below that had an estimate, SPRY beat 10, missed 14 and matched 1. Revenue for the quarter ended Sep 30, 2026 was $37.71M, up 16.0% from $32.50M a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026-$0.36-$0.34-$0.40 - -$0.29-5.88%MissN/A31 up, 2 downNov 5, 2026$37.71M
    Jun 30, 2026-$0.63-$0.55-$0.61 - -$0.36-14.55%MissN/A31 up, 0 downAug 13, 2026$33.66M
    Mar 31, 2026-$0.61-$0.53-$0.67 - -$0.47-15.09%MissN/A40 up, 1 downMay 15, 2026$22.68M
    Dec 31, 2025-$0.42-$0.42N/A+1.08%Beat-182.4%41 up, 0 downMar 9, 2026$28.09M
    Sep 30, 2025-$0.52-$0.49-$0.56 - -$0.46-6.12%MissN/A51 up, 1 downNov 10, 2025$32.50M
    Jun 30, 2025-$0.46-$0.51-$0.66 - -$0.42+9.80%BeatN/A40 up, 1 downAug 13, 2025$15.72M
    Mar 31, 2025-$0.35-$0.36-$0.46 - -$0.31+2.78%BeatN/A40 up, 3 downMay 14, 2025$7.97M
    Dec 31, 2024$0.51-$0.12-$0.31 - $0.28+534.04%BeatN/A42 up, 0 downMar 20, 2025$86.58M
    Sep 30, 2024-$0.20-$0.14-$0.19 - -$0.06-42.86%MissN/A40 up, 0 downNov 13, 2024$2.07M
    Jun 30, 2024-$0.13-$0.11-$0.16 - -$0.09-18.18%MissN/A30 up, 0 downAug 6, 2024$500000
    Mar 31, 2024-$0.11-$0.11-$0.14 - -$0.080.00%In lineN/A20 up, 0 downMay 9, 2024N/A
    Dec 31, 2023-$0.07-$0.14-$0.17 - -$0.11+50.00%Beat-109.1%30 up, 0 downMar 21, 2024N/A
    Sep 30, 2023-$0.16-$0.18-$0.20 - -$0.16+11.11%BeatN/A30 up, 0 downNov 9, 2023N/A
    Jun 30, 2023-$0.18-$0.16-$0.20 - -$0.13-12.50%MissN/A30 up, 0 downAug 10, 2023$10000
    Mar 31, 2023-$0.16-$0.15-$0.19 - -$0.13-6.67%MissN/A30 up, 0 downMay 15, 2023$20000
    Dec 31, 2022$0.77-$0.13-$0.14 - -$0.12+692.31%BeatN/A20 up, 0 downMar 23, 2023N/A
    Sep 30, 2022-$0.50-$0.35N/A-42.86%MissN/AN/AN/ANov 2, 2022$189000
    Jun 30, 2022-$0.55-$0.48N/A-14.58%MissN/AN/AN/AAug 11, 2022$464000
    Mar 31, 2022-$0.70-$0.54N/A-29.63%MissN/AN/AN/AMay 12, 2022$663000
    Dec 31, 2021-$0.67-$0.70N/A+4.29%BeatN/AN/AN/AMar 31, 2022$5.51M
    Sep 30, 2021-$0.65-$0.67N/A+2.99%BeatN/AN/AN/ANov 10, 2021N/A
    Jun 30, 2021-$0.70-$0.53N/A-32.08%MissN/AN/AN/AAug 12, 2021N/A
    Mar 31, 2021-$0.54-$0.35N/A-54.29%MissN/AN/AN/AMay 13, 2021N/A
    Dec 31, 2020-$1.37-$0.49N/A-179.59%MissN/AN/AN/AMar 29, 2021N/A
    Sep 30, 2020-$0.70-$1.10N/A+36.36%BeatN/AN/AN/ANov 10, 2020N/A
    Last 25 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was -$1.75, after $0.07 the year before. It was -$2.07 for the year ended Dec 31, 2020, the oldest of the 6 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025-$1.75-2600.0%
    Dec 31, 2024$0.07N/A
    Dec 31, 2023-$0.57N/A
    Dec 31, 2022-$0.98N/A
    Dec 31, 2021-$2.56N/A
    Dec 31, 2020-$2.07N/A

    Earnings Calls

    The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 3,300 words across 8 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q3Sep 30, 20263,3468
    2026Q2Jun 30, 20263,4728
    2026Q1Mar 31, 20265,0259
    2025Q4Dec 31, 20254,4409
    2025Q3Sep 30, 20256,14611
    2025Q2Jun 30, 20254,3249
    2025Q1Mar 31, 20254,26511
    2024Q4Dec 31, 20248,86411

    2026Q3 Earnings Call

    Opening remarks

    Monique Allaire IR Representative Good afternoon, and thank you all for joining us. With me on the call today are President and CEO, Donn Casale; Chief Commercial Officer, Meg Smith; and our Chief Financial Officer, Kathy Scott. Earlier today, we issued a press release outlining ARS Pharma's commercial highlights and financial results for the third quarter of 2026. That press release can be found in the Investors and Media section of the company's website at ars-pharma.com. Before we begin, please note that today's remarks may contain forward-looking statements, and actual results may differ materially. Please refer to our press release and SEC filings for further risk disclosures. With that, I'll turn the call over to Donn.

    Donn Casale President and CEO Thank you, Monique, and good afternoon, everyone. In August, I outlined a new strategic direction for ARS and laid out 3 corporate priorities to build a durable, profitable business. The first is disrupting the legacy epinephrine market with neffy, delivering steady market share gains through targeted provider commercial execution. The second is reaching cash flow breakeven by year-end 2027 based on greater financial discipline that will continue through 2027. The third is expanding our epinephrine delivery platform beyond anaphylaxis and unlocking value with the potential first on-demand treatment of breakthrough flares in chronic spontaneous urticaria, or CSU. I'm very proud of our progress last quarter and the team's execution against each of these priorities. In the third quarter, neffy continued to capture market share, delivering $33.4 million in U.S. net product revenue. Total U.S. market share surpassed 5%, up from 4% in the third quarter of 2025. This was driven by a 42% year-over-year increase in neffy end-user demand. We recorded more than 19,000 unique prescribers in the third quarter, up 49% year-over-year, for a total of nearly 45,000 prescribers since launch. The impact of our commercial execution is even more evident when you look at market share in field-targeted accounts, which represent about 44% of the total market opportunity. Field-targeted share increased from 6% in Q3 last year to 9% in Q3 this year, compared with 2% in non-targeted accounts. So where our field team engages, neffy wins. On our second priority, we have implemented strict financial discipline that we will maintain going forward. Operating expenses in Q3 were in line with the guidance we selected and set last year, reflecting our ongoing commitment to reducing SG&A spend. SG&A expenses in Q3 were down by more than 40% compared with the prior 2 quarters of this year. Based on our revised expense plan, we affirm that we are on track to achieve cash flow breakeven by year-end 2027.

    Frequently Asked Questions About SPRY

    When is ARS Pharmaceuticals's next earnings date?

    ARS Pharmaceuticals's next earnings report is expected for Mar 8, 2027.

    Did SPRY beat earnings estimates last quarter?

    No. ARS Pharmaceuticals reported EPS of -$0.36 for the quarter ended Sep 30, 2026, below the -$0.34 estimate by 5.88%.

    What EPS do analysts expect from SPRY next quarter?

    The consensus EPS estimate for ARS Pharmaceuticals for the quarter ending Dec 31, 2026 is -$0.31 from 6 analysts, with estimates from -$0.41 to -$0.17.

    How often does SPRY beat earnings estimates?

    ARS Pharmaceuticals beat the EPS estimate in 4 of the last 8 quarters, with an average surprise of +63.26%.